// App-Quantinova.ai

504 : 504: PHEREXA: A phase III Study of Trastuzumab (H) + Capecitabine (X) Pertuzumab (P) for Patients (pts) who Progressed During/After One Line of H-Based Therapy in the HER2-Positive Metastatic Breast Cancer (MBC) Setting

Researchers

Presenter

  • Ander Urruticoechea

Principal Investigators

  • Mohammed Rizwanullah

  • Seock-Ah Im

  • Antonio Carlos Sanchez-Ruiz

  • Istvan Lang

  • Gianluca Tomasello

  • Hannah Douthwaite

  • Tanja Badovinac Crnjevic

  • Sarah Heeson

  • Jennifer Eng-Wong

  • Montserrat Munoz

Medical Centers

  • Onkologikoa Foundation, San Sebastian, Spain

  • Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

  • Hospital Universitario Puerta de Hierro, Madrid, Spain

  • National Institute of Oncology, Budapest, Hungary

  • SC Oncologia, Ospedale di Cremona, Cremona, Italy

  • Roche Products Ltd., Welwyn Garden City, United Kingdom

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • Genentech, Inc., South San Francisico, CA

  • H. Clinic de Barcelona y Genomica Traslacional y Terapias Dirigidas en Tumores Solidos, Barcelona, Spain

Locations

  • Italy

  • Spain

  • United Kingdom

  • Switzerland

  • United States

  • Hungary

Companies

  • Feng Chi Biotech Cor

  • F. Hoffmann-La Roche

  • Genentech, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Capecitabine

  • Trastuzumab

  • Pertuzumab

  • taxane

Outcome

  • Indeterminate

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT01026142

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved